- Home
- WINT vs MGRX Comparison
WINT vs MGRX Comparison
Compare WINT & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- MGRX
- Stock Information
- Founded
- WINT 1992
- MGRX 2021
- Country
- WINT United States
- MGRX United States
- Employees
- WINT N/A
- MGRX N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- MGRX Computer Software: Prepackaged Software
- Sector
- WINT Health Care
- MGRX Technology
- Exchange
- WINT Nasdaq
- MGRX Nasdaq
- Market Cap
- WINT 5.3M
- MGRX 5.8M
- IPO Year
- WINT 1995
- MGRX 2023
- Fundamental
- Price
- WINT $0.50
- MGRX $2.64
- Analyst Decision
- WINT Hold
- MGRX
- Analyst Count
- WINT 1
- MGRX 0
- Target Price
- WINT $18.00
- MGRX N/A
- AVG Volume (30 Days)
- WINT 549.5K
- MGRX 95.3K
- Earning Date
- WINT 11-26-2024
- MGRX 11-14-2024
- Dividend Yield
- WINT N/A
- MGRX N/A
- EPS Growth
- WINT N/A
- MGRX N/A
- EPS
- WINT N/A
- MGRX N/A
- Revenue
- WINT N/A
- MGRX $755,000.00
- Revenue This Year
- WINT N/A
- MGRX N/A
- Revenue Next Year
- WINT N/A
- MGRX N/A
- P/E Ratio
- WINT N/A
- MGRX N/A
- Revenue Growth
- WINT N/A
- MGRX 52.20
- 52 Week Low
- WINT $0.45
- MGRX $2.10
- 52 Week High
- WINT $22.32
- MGRX $16.80
- Technical
- Relative Strength Index (RSI)
- WINT 27.72
- MGRX 47.19
- Support Level
- WINT $0.45
- MGRX $2.26
- Resistance Level
- WINT $0.64
- MGRX $2.51
- Average True Range (ATR)
- WINT 0.06
- MGRX 0.15
- MACD
- WINT 0.07
- MGRX 0.05
- Stochastic Oscillator
- WINT 19.50
- MGRX 75.00
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.